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Preventing Emerging Infectious Diseases: 
A Strategy for the 21st Century
Overview of the Updated CDC Plan
Pathogenic microbes can be resilient, dangerous foes. Although it is impossible to pre-
dict their individual emergence in time and place, we can be confident that new microbial
diseases will emerge.
— Institute of Medicine, Emerging Infections: Microbial Threats to Health in the United
States, 1992
Summary
Societal, technological, and environmental factors continue to have a dra-
matic effect on infectious diseases worldwide, facilitating the emergence of new
diseases and the reemergence of old ones, sometimes in drug-resistant forms.
Modern demographic and ecologic conditions that favor the spread of infectious
diseases include rapid population growth; increasing poverty and urban migra-
tion; more frequent movement across international boundaries by tourists,
workers, immigrants, and refugees; alterations in the habitats of animals and
arthropods that transmit disease; increasing numbers of persons with impaired
host defenses; and changes in the way that food is processed and distributed.
Several recent health events underscore the need for a public health system
ready to address whatever disease problems that might arise. For example,
in 1997, an avian strain of influenza that had never before infected humans
began to kill previously healthy persons in Hong Kong, and strains of  Staphylo-
coccus aureus  with diminished susceptibility to the antibiotic vancomycin were
reported in Japan and the United States. In addition, researchers recently
discovered that a strain of the virus that causes acquired immunodeficiency syn-
drome (AIDS) had been infecting humans for at least 20 years before AIDS
emerged as a worldwide epidemic.
Preventing Emerging Infectious Diseases: A Strategy for the 21st Century
describes CDC’s plan to combat today’s infectious diseases and prevent those of
tomorrow. It represents the second phase of the effort launched in 1994 with the
publication of CDC’s Addressing Emerging Infectious Disease Threats: A Preven-
tion Strategy for the United States. This overview of the updated plan outlines
specific objectives under four major goals: a) surveillance and response, b) ap-
plied research, c) infrastructure and training, and d) prevention and control.
Achieving these objectives will enhance understanding of infectious diseases
and bolster their detection, control, and prevention. The plan also targets nine
categories of problems that cause human suffering and place a burden on soci-
ety. The aim of this plan is to build a stronger, more flexible U.S. public health
system that is well-prepared to respond to known disease problems, as well as
to address the unexpected, whether it be an influenza pandemic, a disease
caused by an unknown organism, or a bioterrorist attack. The implementation of
this plan will require the dedicated efforts of many partners, including state and
local health departments, other federal agencies, professional societies, univer-
sities, research institutes, health-care providers and organizations, the World
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Health Organization, and many other domestic and international organizations
and groups.
INTRODUCTION
Infectious diseases are a continuing threat to all persons, regardless of age, sex,
lifestyle, ethnic background, and socioeconomic status (1 ). They cause suffering and
death and impose a financial burden on society (Table 1) (2–12 ). Although some dis-
eases have been conquered by modern advances such as antibiotics and vaccines,
new ones are constantly emerging (e.g., human immunodeficiency virus and acquired
immunodeficiency syndrome [HIV/AIDS], Lyme disease, and hantavirus pulmonary
syndrome), whereas others reemerge in drug-resistant forms (e.g., malaria, tubercu-
losis, and bacterial pneumonias).
Because no one knows what new diseases will emerge, the public health system
must be prepared for the unexpected. For example, in 1997, an avian strain of influ-
enza that had never before attacked humans began to kill previously healthy persons
in Hong Kong (13 ). This crisis raised the specter of an influenza pandemic similar to
the one that killed 20 million persons in 1918. Also in 1997, strains of Staphylococcus
TABLE 1. Annual national costs and charges* associated with some infectious diseases
— United States, selected years (1991–1993)
Disease Annual cost Type of cost
Acquired immunodeficiency
syndrome (2 )
$5.8 billion Direct medical charges,
(1993 dollars)
Tuberculosis (3 ) $703 million Direct medical charges,
(1991 dollars)
Nosocomial infections
(acquired in hospital) (4 )
$4.5 billion Hospital charges
(1992 dollars)
Foodborne bacteria (5 ) $2.9–$6.7 billion† Direct and indirect costs
(1993 dollars)
Human papillomavirus (6–10 ) $1.23 billion§ Direct medical charges
(1991 dollars)
Neonatal group B
streptococcal infections (11 )
$294 million Direct medical charges
(1993 dollars)
Bacterial vaginosis (12 ) $1.0 billion Direct medical charges
(1993 dollars)
*Costs are actual economic costs whereas charges reflect the amount charged by a health-care
provider.
†This range is for the combined direct and indirect costs associated with foodborne illnesses
caused by six pathogens: Campylobacter jejuni or Campylobacter coli; Clostridium perfringens;
Escherichia coli O157:H7; Listeria monocytogenes; Salmonella (nontyphoid); and Staphylococ-
cus aureus.
§Preliminary estimates are based on the fact that human papillomavirus causes 82% of all
cervical cancers (6–8 ); thus, charges were calculated by assuming that 82% of the following
treatment charges are attributable to human papillomavirus: follow-up of precancerous lesions
identified by Pap smear (1 million follow-up visits costing $1,100 each for a total of $1.1 billion)
(6–10 ), treatment of carcinoma in situ (55,000 treatments costing $4,360 each, for a total of
$0.2 billion) (6–9 ), and treatment of cervical cancer (15,800 treatments costing $11,300 each,
for a total of $0.2 billion) (6–10 ). These estimates do not include indirect costs attributable to
lost productivity or the cost of screening for cervical cancer.
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aureus with diminished susceptibility to vancomycin were reported in Japan and the
United States (14 ). If drugs like vancomycin cannot be replaced as they lose their
effectiveness — or if the emergence and spread of drug resistance cannot be limited
— some diseases might become untreatable, as they were in the preantibiotic era. In
addition, the recent discovery that a strain of the virus that causes HIV/AIDS has been
infecting humans at least since 1959 (15 ) illustrates how infectious agents can remain
undetected for years before emerging as public health problems. Each of these inci-
dents underscores the need for a public health infrastructure that is ready to address
whatever disease problems that might arise.
Preventing Emerging Infectious Diseases: A Strategy for the 21st Century (16 ) de-
scribes steps that can be taken to move toward realizing CDC’s vision of a world in
which individuals, communities, and nations join in a common effort to combat to-
day’s emerging infectious diseases and prevent those of tomorrow. Copies of the plan
will be available from the Office of Health Communication, National Center for Infec-
tious Diseases (NCID), Centers for Disease Control and Prevention, Mail Stop C-14,
1600 Clifton Road, Atlanta, GA 30333. The plan also can be accessed from the NCID
home page at <http://www.cdc.gov/ncidod/publicat.htm>.
CDC’s PLAN TO PREVENT EMERGING INFECTIOUS DISEASES
Preventing Emerging Infectious Diseases: A Strategy for the 21st Century repre-
sents the second phase of CDC’s plan to revitalize the country’s capacity to protect the
public from infectious diseases, an effort that was launched in 1994 with the publica-
tion of Addressing Emerging Infectious Disease Threats: A Prevention Strategy for the
United States (17 ). During the past 4 years, CDC has implemented the 1994 plan incre-
mentally, with the help of many partners. By fiscal year 1997, funds were available to
implement about one third of the recommended programs and activities, which fo-
cused on improving surveillance, conducting applied research, rebuilding the public
health infrastructure, and strengthening efforts to prevent emerging infectious dis-
eases.
CDC decided to update its plan in 1998 because of recent developments (see page
4, Events Prompting CDC to Update the 1994 Plan [18–31 ]) and because of the need to
build on achievements from implementing the 1994 plan (see Appendix to the 1998
plan [16 ]). Preventing Emerging Infectious Diseases: A Strategy for the 21st Century
takes into account the new discoveries and challenges of the past 4 years and builds
on the experience, accomplishments, and knowledge gained from implementing the
1994 plan.
Persons from approximately 50 organizations contributed to the development of
the updated plan; they and many other partners will be essential to the plan’s imple-
mentation. CDC will implement the plan in coordination with state and local health
departments (e.g., on surveillance of infectious diseases), academic centers and other
federal agencies (e.g., on research agendas), health-care providers and organizations
(e.g., on development and dissemination of guidelines), international organizations
(e.g., on outbreak responses overseas), and many other partners.
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Events Prompting CDC to Update the 1994 Plan
CDC decided to update its strategy for addressing emerging infectious diseases because
of progress in implementing the highest priorities in the 1994 plan as well as several recent
developments:
Emerging Threats
• A new variant of a fatal neurologic illness, Creutzfeldt-Jakob disease, appeared in the
United Kingdom and was possibly transmitted by ingestion of beef from animals af-
flicted with bovine spongiform encephalopathy, also known as “mad cow disease.”
This disease might be caused by a newly recognized type of transmissible agent called
a prion (18 ).
• A new and virulent strain of influenza in Hong Kong raised fears of a global pandemic
(13 ).
• The United States had several multistate foodborne outbreaks, including outbreaks
caused by Cyclospora parasites on fresh raspberries (19 ); hepatitis A virus on frozen
strawberries (20 ); and Escherichia coli O157:H7 bacteria in apple cider, lettuce, alfalfa
sprouts, and ground beef (21–22 ).
• Staphylococcus aureus with reduced susceptibility to vancomycin — the only antibiotic
that remains effective against some strains of this bacterium — was reported for the
first time in the United States and Japan (14 ).
• A new strain of tuberculosis (strain W), which is multidrug-resistant and appears more
frequently in persons with HIV infection, has become endemic in New York (23 ).
Scientific Findings
• Scientists have found increasing evidence that certain infectious microbes cause or con-
tribute to the development of some chronic diseases (24 ). 
• Many human genes have been discovered that influence a person’s susceptibility to
infection, severity of infection, and responsiveness to vaccination or treatment (25 ).
Tools and Technologies
• Electronic communications are linking public health institutions in most areas of the
world, providing a constant and enormous stream of information on infectious disease
outbreaks and related health issues.
• Innovations in biotechnology are making it easier to identify and track strains of infec-
tious microbes and to determine the causes and sources of outbreaks as well as the
routes of disease transmission. 
Changes in Health-Care Delivery
• Large numbers of Americans have switched from fee-for-service medical insurance to
various types of managed care. The shift to managed care has created new challenges
and opportunities for disease prevention, surveillance, control, and research. Because
of their structures, managed care organizations are in a good position to conduct sur-
veillance, answer clinical research questions, and effect changes in medical practice
(e.g., implementation of guidelines).
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Goals and Objectives
The objectives of Preventing Emerging Infectious Diseases: A Strategy for the 21st
Century are organized under four goals: surveillance and response, applied research,
infrastructure and training, and prevention and control. Under each objective, the plan
describes in detail the many public health activities that must be conducted to imple-
ment CDC’s strategy.
Goal I — Surveillance and Response. Detect, investigate, and monitor emerging
pathogens, the diseases they cause, and the factors influencing their emergence, and
respond to problems as they are identified.
Objectives
• Strengthen infectious disease surveillance and response. For example, this ob-
jective includes expanding and creating programs, networks, and surveillance
systems that enable health departments nationwide to identify and respond to
infectious disease threats.
• Improve methods for gathering and evaluating surveillance data.
• Ensure the use of surveillance data to improve public health practice and medical
treatment.
• Strengthen global capacity to monitor and respond to emerging infectious dis-
eases.
Events Prompting CDC to Update the 1994 Plan — Continued
• Shortened hospital stays for some conditions have made it necessary to develop new
ways to monitor certain patient outcomes, including hospital-acquired infections whose
symptoms do not appear until after the patient has left the hospital.
• Home health care has become the fastest growing sector of the U.S. health-care indus-
try (26 ). New public health partnerships and new methods for assessment are needed
to monitor the impact of treatments and to measure the occurrence of health-care–
related infections in home health-care settings.
Public and Policy Issues
• Many Americans have learned about new diseases like Ebola hemorrhagic fever
through media reports, films and television movies, and books (27–29 ). In addition,
they might know somebody who has suffered from an emerging infectious disease or
an antibiotic-resistant infection.
• In 1995, a policy report issued by the Committee on International Science, Engineering,
and Technology (CISET) of the National Science and Technology Council recommended
governmentwide action to combat emerging infectious diseases (30 ). 
• In 1996, a Presidential Decision Directive on emerging infectious diseases established a
new national policy to address the growing health and national security threat posed by
infectious diseases, including the potential threat of bioterrorism (31 ).
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The objectives and activities of Goal I reflect recent changes in needs and capabili-
ties for surveillance and response. For instance, outbreaks of foodborne illness used
to be primarily local events that were easily recognized. Now, however, outbreaks
often involve persons scattered over wide geographic areas — the consequence of
regional, national, or international distribution of food products. In recent years,
through various coordinated efforts including the 1997 National Food Safety Initiative,
the U.S. Food and Drug Administration, U.S. Department of Agriculture, CDC, and
other  agencies have begun to enhance national capacity to track and respond to food-
borne illnesses across the country. In mid-1998, the Secretary of Health and Human
Services announced PulseNet — a national network of laboratories that perform DNA
fingerprinting of bacteria isolated from patients and contaminated food. The network
permits rapid comparison of molecular fingerprint patterns through an electronic da-
tabase at CDC. When patterns submitted from different sites are identical, the
computer alerts health agencies to a possible widespread outbreak of foodborne ill-
ness (see page 7,  Pulsed-Field Gel Electrophoresis Patterns of Escherichia coli
O157:H7 Isolates — Washington State, 1996). During the next several years, CDC will
continue to develop PulseNet in partnership with state health departments and the
Association of Public Health Laboratories, increasing the number of participating labo-
ratories and the number of organisms covered.
PulseNet demonstrates how CDC and its partners can use modern laboratory tech-
niques and electronic communications to strengthen disease surveillance and
response. The objectives and activities described under Goal I address the need for a
strong and coordinated system for surveillance and response in the United States and
abroad, not only for foodborne diseases but for other emerging infectious diseases as
well. They call for increased links among surveillance sites, improved tools and ap-
proaches for conducting surveillance, as well as prompt and effective translation of
surveillance data into public health action.
Goal II — Applied Research. Integrate laboratory science and epidemiology to optimize
public health practice.
Objectives
• Develop, evaluate, and disseminate tools for identifying and understanding
emerging infectious diseases.
• Identify the behaviors, environments, and host factors that put persons at in-
creased risk for infectious diseases and their sequelae.
• Conduct research to develop and evaluate prevention and control strategies in
nine target areas (see Target Areas).
Research is essential in efforts to understand, prevent, control, and respond to new
and reemerging infectious diseases. Much of CDC’s emerging infectious disease re-
search is laboratory-based or epidemiologic, often performed in response to an
emergency such as an outbreak of disease. In addition, CDC conducts studies in
nonoutbreak settings to evaluate prevention strategies and identify factors that put
persons at increased risk. 
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For example, between 1993 and 1995, in partnership with several other organiza-
tions, CDC conducted Project Respect — a randomized trial of alternative approaches
to counseling persons who visit medical clinics about how to prevent HIV and other
sexually transmitted diseases (STDs). One group received simple educational mes-
sages, and the other received intensive counseling that focused on the client’s
personal situation. After 6 months, persons who received client-centered counseling
were substantially more likely to use condoms 100% of the time and had substantially
fewer new STDs (32 ). At 12 months, rates of condom use were similar in the two
groups, but the reduced rate of new STDs persisted among persons who received
client-centered counseling. CDC and other Project Respect investigators are translat-
ing these research findings into prevention programs that can be delivered in other
clinical settings. Project Respect is an example of the type of prevention research ef-
forts that will be conducted under Goal II. 
Pulsed-Field Gel Electrophoresis Patterns of Escherichia coli  O157:H7 Isolates —
Washington State, 1996
This illustration shows the relationships among DNA fingerprints of Escherichia coli
O157:H7 isolates from Washington State. Patterns of the two isolates from apple juice are
identical to patterns of isolates from patients who drank the contaminated juice but different
from patterns of isolates from patients whose infections were not juice-related. This tech-
nology, known as pulsed-field gel electrophoresis (PFGE), has been useful in the
investigation of many outbreaks of foodborne illnesses, especially those that involve clus-
ters of cases that are too geographically or temporally scattered to come to public health
attention through usual methods of surveillance. For example, in 1997, the Colorado De-
partment of Public Health and Environment used PFGE to detect a small cluster of cases
of E. coli O157:H7 infection. Each ill person had eaten the same brand of frozen hamburger
patty. Twenty-five million pounds of ground beef were recalled, and a potentially nationwide
outbreak was averted. 
E. coli isolates from patients
whose infections were not 
juice-related
E. coli isolates from patients
who drank contaminated juice
Juice isolates
D
en
dr
og
ra
m
*
1009080
1009080
*Vertical line at 100% represents isolates that are indistinguishable from each other. Lines
farther away from 100% on the dendrogram represent isolates that are similar to the
outbreak isolates but are not a perfect match.
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Goal III — Infrastructure and Training. Strengthen public health infrastructures to
support surveillance and research and to implement prevention and control programs.
Objectives
• Enhance epidemiologic and laboratory capacity.
• Improve CDC’s ability to communicate electronically with state and local health
departments, U.S. quarantine stations, health-care professionals, and others. 
• Enhance the nation’s capacity to respond to complex infectious disease threats in
the United States and internationally, including outbreaks that may result from
bioterrorism.
• Provide training opportunities in infectious disease epidemiology and diagnosis
in the United States and throughout the world.
The public health infrastructure is the underlying foundation that supports the plan-
ning, delivery, and evaluation of public health activities and practices. For example, a
strong public health infrastructure is needed to ensure that the public is safe from
vaccine-preventable diseases like polio, measles, and diphtheria, as well as rubella, an
acute viral infection that can cause severe birth defects in babies born to infected
mothers. Although no major epidemics of childhood rubella have occurred in the
United States since the introduction of rubella vaccine in 1969 (33 ), rubella cases have
increased recently among adults, particularly among persons who come from coun-
tries without rubella vaccination programs (34 ). This increase places susceptible
pregnant women and their fetuses at risk (34 ).
The North Carolina Department of Environment, Health, and Natural Resources’
handling of a 1997 rubella outbreak exemplifies the kinds of activities called for under
Goal III. The outbreak, which affected nine of the state’s counties, occurred shortly
after a rubella surveillance system had been established, and the outbreak was de-
tected early. Health workers visited the homes and workplaces of infected persons and
vaccinated friends of patients, family members, and fellow employees. Pregnant
women who potentially were exposed received medical follow-up. The outbreak was
contained, and no cases of congenital rubella syndrome were reported. North Caro-
lina’s rubella surveillance system was established with funding from CDC, which since
1994 has provided grants to state and large city health departments for establishing
systems to monitor and track vaccine-preventable diseases.
The objectives and activities described under Goal III will help ensure that in future
years state and local health departments have the equipment, staff, and training to
respond to emerging infectious disease threats in the Untied States, whether they be
outbreaks of rubella, drug-resistant microbes, or acts of bioterrorism. Because
microbes can cover wide geographic areas and span borders between nations, the
objectives and activities of Goal III also address the need to help build global infra-
structure to combat emerging infectious diseases.
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Goal IV — Prevention and Control. Ensure prompt implementation of prevention
strategies and enhance communication of public health information about emerging
diseases.
Objectives
• Implement, support, and evaluate programs for the prevention and control of
emerging infectious diseases. 
• Develop, evaluate, and promote strategies to help health-care providers and
other persons change behaviors that facilitate disease transmission.
• Support and promote disease control and prevention internationally.
All of the goals and objectives in this plan ultimately are directed at preventing and
controlling infectious diseases. For example, a national effort to prevent the transmis-
sion of group B streptococcal infection to newborns is based on ongoing disease
surveillance (Goal I), multidisciplinary research (Goal II), and strong local public health
infrastructures (Goal III).
One of five women carries group B streptococcal bacteria, although the infections
are usually asymptomatic (35,36 ). When transmitted from an infected pregnant
woman to her newborn during childbirth, however, the bacteria can cause severe
health problems for the baby and even result in death (37 ). Although studies in the
1980s documented that administering antibiotics during childbirth to women at high
risk could prevent group B streptococcal infection in newborns (36 ), a study com-
pleted in 1990 determined that thousands of U.S. babies continued to be infected each
year, primarily because antibiotics were not always administered when needed (37 ).
CDC has responded to this problem by working with public and private organizations
to develop and distribute new recommendations for disease prevention (36 ). Be-
tween 1993 and 1995, as obstetricians adopted the new policies, the incidence of
neonatal group B streptococcal infections declined by as much as 43% in some areas
(38 ) and continued to decline through 1997 (personal communication, Anne
Schuchat, M.D., CDC, 1998). CDC is continuing to work with community groups, health
departments, and professional organizations to bring standardized prevention proto-
cols to a wider audience (39 ).
As demonstrated by this example, preventing and controlling emerging infectious
diseases requires the combined and coordinated work of many persons and organiza-
tions. The objectives and activities in Goal IV emphasize the need for strong partner-
ships to address emerging infectious disease problems.
Target Areas
To accomplish these goals, objectives, and activities, Preventing Emerging Infec-
tious Diseases: A Strategy for the 21st Century targets nine categories of problems
that cause human suffering and place a burden on society:
• Antimicrobial resistance. The emergence of drug resistance in bacteria, para-
sites, viruses, and fungi is reversing advances of the previous 50 years (Figure 1).
As the 21st century approaches, many important drug choices for the treatment
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of common infections are becoming increasingly limited, expensive, and, in
some cases, nonexistent.
• Foodborne and waterborne diseases. Changes in the ways that food is processed
and distributed are causing more multistate outbreaks of foodborne infections. In
addition, a new group of waterborne pathogens has emerged that is unaffected
by routine disinfection methods. 
• Vectorborne and zoonotic diseases. Many emerging or reemerging diseases
are acquired from animals or are transmitted by arthropods. Environmental
changes can affect the incidence of these diseases by altering the habitats of dis-
ease vectors. 
• Diseases transmitted through blood transfusions or blood products. Improve-
ments in blood donor screening, serologic testing, and transfusion practices
have made the U.S. blood supply one of the safest in the world, despite its size
and complexity. However, because blood is a human tissue, it is a natural vehicle
for transmitting infectious agents. Therefore, continued vigilance is needed to
ensure the safety of the U.S. blood supply.
• Chronic diseases caused by infectious agents. Several chronic diseases once at-
tributed to lifestyle or environmental factors (e.g., some forms of cancer, heart
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FIGURE 1. High and intermediate levels of penicillin resistance in Streptococcus
pneumoniae — United States, 1979–1997*
*During the 1980s, more than 90% of Streptococcus pneumoniae isolates in the United States
were sensitive to penicillin, and high-level resistance to penicillin was not observed. By 1997,
however, one in four isolates exhibited some degree of resistance to penicillin; one in seven
isolates exhibited high-level resistance.
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disease, and ulcers) might be caused or intensified by infectious agents (24 ).
This new knowledge raises the possibility that certain chronic diseases might
someday be treated with antimicrobial drugs or prevented by vaccines.
• Vaccine development and use. Certain childhood diseases (e.g., diphtheria,
tetanus, polio, measles, mumps, rubella, and Haemophilus influenzae type b
disease) have been virtually eliminated in the United States through universal
vaccination. However, additional vaccines are needed to prevent diseases that
are a societal burden in the United States or internationally (e.g., HIV/AIDS, den-
gue fever, hepatitis C, and malaria).
• Diseases of persons with impaired host defenses. Persons whose normal host
defenses against infection have been impaired by illness, by medical treatment,
or as a result of age are more likely to become ill with various infectious diseases.
Infections that occur with increased frequency or severity in such persons are
called opportunistic infections. Health-care providers and scientists must be
ready to identify and investigate each new opportunistic infection as it appears,
and to learn how to diagnose, treat, control, and prevent it.
• Diseases of pregnant women and newborns. Certain asymptomatic infections in
a pregnant woman can increase her infant’s risk of prematurity, low birth weight,
long-term disability, or death. In addition, infections can be transmitted from
mother to child during pregnancy, delivery, or breast-feeding. Effective and ac-
cessible prenatal care is essential to the prevention of infection in pregnant
women and newborn babies. 
• Diseases of travelers, immigrants, and refugees. Persons who cross international
boundaries (e.g., tourists, workers, immigrants, and refugees) are at increased
risk for contracting infectious diseases and can also disseminate diseases to new
places. International air travel has increased substantially in recent years, and
more travelers are visiting remote locations where they can be exposed to infec-
tious agents that are uncommon in their native countries.
ANTICIPATED OUTCOMES
Achievement of the objectives described in this plan will improve understanding of
infectious diseases and bolster their detection, control, and prevention. The goal of
this plan is a stronger, more flexible U.S. public health system that is well prepared to
respond to known disease problems and to address the emergence of new infectious
pathogens. Implementation of this plan will produce the following results:
• A nationwide network for surveillance and response will ensure the prompt iden-
tification of emerging infectious diseases. State and local health departments will
have the equipment and trained personnel needed to provide the front-line
public health response to infectious disease threats.
• Intensive population-based surveillance and research programs in at least 10 ar-
eas of the United States will generate data to identify new threats to public health
and help guide responses to emerging infectious diseases.
Vol. 47 / No. RR-15 MMWR 11
• State health departments will rapidly detect and investigate outbreaks of food-
borne illnesses by using sophisticated epidemiologic and laboratory techniques.
Early detection will facilitate the rapid implementation of control measures and
the prevention of illness and death.
• Countries in all regions of the world will participate in a global system for surveil-
lance and response that includes surveillance for infectious agents that are
resistant to antimicrobial drugs. This effort will be undertaken in partnership with
the World Health Organization and other organizations and agencies around the
world.
• Enhancement of the public health infrastructure will help prepare the United
States to respond to bioterrorist incidents. 
• Improved diagnostic testing methods will be developed for new, reemerging,
and drug-resistant pathogens.
• A better understanding of risk factors for the development of infection and dis-
ease will provide new opportunities for disease prevention. 
• A better understanding of relationships between infectious agents and some
chronic diseases will lead to new strategies for preventing and treating chronic
diseases.
• New strategies will be designed to reduce insect vector populations and control
animal populations that serve as reservoirs for human diseases.
• Diagnostic and reference reagents will be available for use by public health labo-
ratories. CDC will have enhanced capacity to serve as the national reference
center for diagnosis of infectious diseases and for drug-resistance testing.
• The next generation of epidemiologists and laboratorians will be trained and pre-
pared to respond to emerging infectious disease threats.
• Implementation of prevention guidelines will result in decreased death and
disability caused by nosocomial infections, opportunistic infections, antimicro-
bial resistance, and infections in newborns.
• Cooperative efforts among managed care organizations, health-care facilities,
state and local health departments, and CDC will improve treatment and preven-
tion of infectious diseases.
• Deaths from vaccine-preventable diseases will be substantially reduced in the
United States and abroad.
• Community-based demonstration programs will help identify cost-effective ap-
proaches to addressing emerging infectious disease problems.
12 MMWR September 11, 1998
References
1. Institute of Medicine. Emerging infections: microbial threats to health in the United States.
Washington, DC: National Academy Press, 1992.
2. Farnham PG. Defining and measuring the costs of the HIV epidemic to business firms. Public
Health Rep 1994;109:311–8.
3. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United
States. Arch Intern Med 1995;155:1595–1600.
4. Martone WJ, Jarvis WR, Culver DH, Haley RW. Incidence and nature of endemic and epidemic
nosocomial infections. In Bennett JV, Brachman PS, eds. Hospital infections. Third edition.
Boston, MA: Little, Brown and Company, 1992.
5. Buzby JC, Roberts T, Lin C-TJ, MacDonald JM. Bacterial foodborne disease: medical costs
and productivity losses. Agricultural economic report No. 741. Washington, DC: U.S. Depart-
ment of Agriculture, Food and Consumer Economics Division, Economic Research Service,
1996.
6. Schiffman MH, Brinton LA, Devesa SS, Fraumeni JF Jr. Cervical cancer. In Schottenfeld D,
Fraumeni JF Jr., eds. Cancer epidemiology and prevention. Second edition. New York, NY:
Oxford University Press, 1996.
7. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable
fraction in 1990. Cancer Epidemiol Biomarkers Prevent 1997;6:387–400.
8. Roland PY, Naumann RW, Alvarez RD, Kilgore LC, Partridge EE. A decision analysis of practice
patterns used in evaluating and treating abnormal Pap smears. Gynecol Oncol 1995;59:75–80.
9. Jones HW. Impact of the Bethesda System. Cancer 1995;76:1914–8.
10. Fahs MC, Mandelblatt J, Schechter C, Muller C. Cost effectiveness of cervical cancer screening
for the elderly. Ann Intern Med 1992;117:520–7.
11. Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention
strategies for neonatal group B streptococcal infection: a population-based economic analysis.
JAMA 1993;270:1442–8.
12. Oleen-Burkey MA, Hillier SL. Pregnancy complications associated with bacterial vaginosis and
their estimated costs. Infect Dis Obstet Gynecol 1995;3:149–57.
13. CDC. Isolation of avian influenza A(H5N1) viruses from humans — Hong Kong, May–Decem-
ber 1997. MMWR 1997;46:1204–7.
14. CDC. Staphylococcus aureus with reduced susceptibility to vancomycin — United States, 1997.
MMWR 1997;46:765–6 [see also erratum in MMWR 1997;46:851].
15. Zhu T, Korber B, Nahmias AJ, Hooper E, Sharp PM, Ho DD. An African HIV-1 sequence from
1959 and implications for the origin of the epidemic. Nature 1998;391:594–7.
16. CDC. Preventing emerging infectious diseases: a strategy for the 21st century. Atlanta, GA:
CDC, in press. 
17. CDC. Addressing emerging infectious disease threats: a prevention strategy for the United
States. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service,
1994.
18. Prusiner SB. Prions. In Fields BN, Knipe DM, Howley PM, et al., eds. Virology. Third edition.
Philadelphia, PA: Lippincott-Raven, 1996.
19. Herwaldt BL, Ackers ML. An outbreak in 1996 of cyclosporiasis associated with imported rasp-
berries. The Cyclospora Working Group. N Engl J. Med 1997;336:1548–56.
20. CDC. Hepatitis A associated with consumption of frozen strawberries — Michigan, March 1997.
MMWR 1997;46:288, 295.
21. CDC. Outbreaks of Escherichia coli O157:H7 infection and cryptosporidiosis associated with
drinking unpasteurized apple cider — Connecticut and New York, October 1996. MMWR 1997;
46:4–8.
22. CDC. Outbreaks of Escherichia coli O157:H7 infection associated with eating alfalfa sprouts
— Michigan and Virginia, June–July 1997. MMWR 1997;46:741–4.
23. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant
tuberculosis: epidemiology and clinical outcomes. JAMA 1996;276:1229–35.
24. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: a recon-
sideration of Koch’s postulates. Clin Microbiol Rev 1996;9:18–33.
25. Hill AV. Genetics of infectious disease resistance. Curr Opin Genet Dev 1996;6:348–53.
Vol. 47 / No. RR-15 MMWR 13
26. Garret DO, Jarvis WR. The expanding role of healthcare epidemiology — home and long-term
care. Infect Control Hosp Epidemiol 1996;17:714–7.
27. Preston R. The hot zone. New York, NY: Random House, 1994.
28. Garrett L. The coming plague: newly emerging diseases in a world out of balance. New York,
NY: Farrar, Straus, and Giroux, 1995.
29. Peters CJ, Olshaker M. Virus hunter: thirty years of battling hot viruses around the world.
New York, NY: Bantam, Doubleday, Dell, 1997.
30. Working Group on Emerging and Re-emerging Infectious Diseases, Committee on Interna-
tional Science, Engineering, and Technology, National Science and Technology Council.
Infectious disease — a global health threat. Washington, DC: U.S. Government Printing Office,
1995.
31. Office of Science and Technology Policy, the White House. Fact sheet: addressing the threat
of emerging infectious diseases. Washington, DC: The White House, June 12, 1996.
32. Kamb ML, Bolan G, Zenilman J, et al. Does HIV/STD prevention counseling work?  Results
from a multi-center randomized trial (Project Respect). Presented at the 12th meeting of the
International Society of Sexually Transmitted Diseases Research, October 19–22, 1997, Seville,
Spain.
33. CDC. Rubella and congenital rubella syndrome — United States, 1994-1997. MMWR 1997;
46:350–4.
34. CDC. Rubella and congenital rubella syndrome — United States, January 1, 1991–May 7, 1994.
MMWR 1994;43:391–401.
35. Baker CJ, Edwards MS. Group B streptococcal infections. In Remington JS, Klein JO, eds.
Infectious diseases of the fetus and newborn infant. 4th ed. Philadelphia, PA: WB Saunders,
1995:980–1054.
36. CDC. Prevention of perinatal group B streptococcal disease: a public health perspective.
MMWR 1996;45(No. RR-7):1–24.
37. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States,
1990: report from a multistate active surveillance system. MMWR 1992;41(No. SS-6):25–32.
38. CDC. Decreasing incidence of perinatal group B streptococcal disease — United States, 1993–
1995. MMWR 1997;46:473–7.
39. CDC. Adoption of hospital policies for prevention of perinatal group B streptococcal disease
— United States, 1997. MMWR 1998;47:665–70.
14 MMWR September 11, 1998
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control
and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis
for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to
listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is
available from CDC’s World-Wide Web server at http://www.cdc.gov/ or from CDC’s file transfer protocol
server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government
Printing Office, Washington, DC 20402; telephone (202) 512-1800.
Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments.
The reporting week concludes at close of business on Friday; compiled data on a national basis are officially
released to the public on the following Friday. Address inquiries about the MMWR Series, including material
to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta,
GA 30333; telephone (888) 232-3228.
All material in the MMWR Series is in the public domain and may be used and reprinted without
permission; citation as to source, however, is appreciated.
IU.S. Government Printing Office: 1998-633-228/87023 Region IV
MMWR
